The company
DBV Technologies S.A. - American Depositary Shares
DBVT · Nasdaq
DBVT stood above a rising 150-day average in 31 of the last 52 weekly readings, and has been out of that trend for the last 20 weeks. It is 43.8% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 20
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $15.5M
- Officials’ trades on record
- 6
- Institutions holding
- 75 (+7)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 31 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
6 disclosed lines: House 6, Senate 0, executive 0; 1 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| James B. Renacci House: U.S. House ClerkOH16 | sold | $15k–$50k | 15 Dec 2017filed 21 Dec 2017 |
| James B. Renacci House: U.S. House ClerkOH16 | bought | $1k–$15k | 8 Mar 2016filed 23 Mar 2016 |
| James B. Renacci House: U.S. House ClerkOH16 | bought | $1k–$15k | 29 Jan 2016filed 8 Feb 2016 |
| James B. Renacci House: U.S. House ClerkOH16 | bought | $1k–$15k | 11 Jan 2016filed 27 Jan 2016 |
| James B. Renacci House: U.S. House ClerkOH16 | sold | $1k–$15k | 9 Dec 2015filed 21 Dec 2015 |
| James B. Renacci House: U.S. House ClerkOH16 | bought | $1k–$15k | 10 Nov 2015filed 23 Nov 2015 |
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Pharis MohideenChief Medical Officer | sold | 464at $2.70 | 29 Jul 2026filed 31 Jul 2026 |
| Pharis MohideenChief Medical Officer | sold | 534at $4.86 | 29 Jan 2026filed 2 Feb 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| MPM BIOIMPACT LLCreduced · filed 14 Aug 2026 | 3,666,284$60.1M | -1,547,077−29.7% |
| Siren, L.L.C.unchanged · filed 13 Aug 2026 | 1,857,362$30.5M | 00.0% |
| Vivo Capital, LLCreduced · filed 14 Aug 2026 | 1,844,758$30.3M | -822,811−30.8% |
| PERCEPTIVE ADVISORS LLCadded · filed 14 Aug 2026 | 1,653,350$27.1M | +688,959+71.4% |
| BAKER BROS. ADVISORS LPunchanged · filed 14 Aug 2026 | 1,461,425$24.0M | 00.0% |
| Artisan Partners Limited Partnershipreduced · filed 13 Aug 2026 | 1,372,851$22.5M | -846,535−38.1% |
| UBS Group AGadded · filed 13 Aug 2026 | 1,313,439$21.5M | +1,233,902+1551.4% |
| MORGAN STANLEYadded · filed 13 Aug 2026 | 954,908$15.7M | +808,792+553.5% |
| Logos Global Management LPnew · filed 14 Aug 2026 | 915,000$15.0M | +915,000 |
| Patient Square Capital LPadded · filed 12 Aug 2026 | 909,474$14.9M | +215,940+31.1% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.